Category: Bruker Corp.Syndicate content

Guidant didn't breach deal with J&J, says lawyer | Medtech legal news for the week of December 22, 2014

December 22, 2014 by MassDevice

Here's a look at some of the top legal news stories for medical device companies this week: Lawyer says Guidant didn't breach deal with J&J; Ex-Abbott stent liaison alleges retaliation for compliance complaint; Trial date set for Boston Scientific executive's accused killer; Analogic expects fines in BK Medical's Danish bribery beef; SEC dings Bruker in $2.4m China bribery case

Report: Lawyer says Guidant didn't breach deal with J&J

December 16, 2014 by Brad Perriello

YYmeta

SEC dings Bruker in $2.4m China bribery case

December 15, 2014 by Brad Perriello

The SEC dings Bruker Corp. for $2.4 million to settle charges that it broke the Foreign Corrupt Practices Act by paying off Chinese officials to win business there but admitted no wrongdoing.

SEC dings Bruker in $2.4m China bribery case

Get the complete picture with a MassDevice Plus membership. Registered users can login here.

ConMed closes tender offer for Viking Systems | Wall Street Beat

September 24, 2012 by MassDevice staff

ConMed closes its 27¢-per-share tender offer for medical imaging company Viking Systems, giving it about 84% of Viking as it looks to close its short-form merger.

MassDevice.com Wall Street Beat

ConMed (NSDQ:CNMD) said it's closed its 27¢-per-share tender offer for Viking Systems (OTC:VKNG), leaving it with about 84% of shares in the medical imaging maker.

Get the complete picture with a MassDevice Plus membership. Registered users can login here.

Bruker tanks on Q2 earnings forecast | Wall Street Beat

July 24, 2012 by MassDevice staff

Shares of Bruker Corp. are down nearly 12% today after the medical device company cut its earnings forecast in half.

MassDevice.com Wall Street Beat

Bruker Corp. (NSDQ:BRKR) shares took a double-digit dive this morning after the medical device company said it expects the European fiscal crisis to cut its 2ns-quarter per-share earnings roughly in half.

Bruker said it expects to report adjusted EPS of 11¢-13¢ for the 3 months ended June 30, on sales of about $420 million. Wall Street analysts were expecting adjusted EPS of 21¢.

Bruker names Charles Wagner Jr. CFO | Personnel Moves

June 7, 2012 by MassDevice staff

Bruker Corp. named former board member Charles Wagner Jr. it's new CFO and executive vice president.

fired/hired

 Bruker names Charles Wagner Jr. executive VP and CFO

Get the complete picture with a MassDevice Plus membership. Registered users can login here.

Boston Scientific launches Pluromed's BackStop kidney stone treatment | Wall Street Beat

April 2, 2012 by MassDevice staff

Boston Scientific launches its BackStop kidney stone treatment, licensed from Pluromed, in the U.S. and certain international markets; also, Siemens lands 3rd year defense contract worth up to $1.9 billion; Bruker Corp. nabs all shares of SkyScan for an undisclosed amount; Viking expects 40% sales growth for Q1 2012; Smith & Nephew acquires LifeModeler for an undisclosed amount; Wound Care Innovations signs exclusive N.A.

MassDevice.com Wall Street Beat

Boston Scientific (NYSE:BSX) launched its BackStop kidney stone treatment product in the U.S. and certain international markets this week.

Get the complete picture with a MassDevice Plus membership. Registered users can login here.

Is J&J in the hunt for Boston Scientific? | Acquisitions Roundup

September 15, 2011 by MassDevice staff

Could the installation of Johnson & Johnson's top medical device exec as bitter rival Boston Scientific's new CEO could signal the conglomerate's interest in acquiring BSX?; also, Integra to pay $65 million for Ascension Orthopedics; Solta Medical buys LipoSonix from Medicis for $15 million; Vasomedical buys Chinese suppliers; Hill-Rom pays $20 million for French, Swiss distributors; Bruker to buy CETR; Elekta closes Nucletron deal; and DGT Holdings deals Italian subsidiary to VIV for $22.5 million.

Johnson & Johnson
Boston Scientific

Could the amicable deal between bitter rivals Johnson & Johnson (NYSE:JNJ) and Boston Scientific (NYSE:BSX) over Michael Mahoney leaving J&J to helm BSX signal an upcoming acquisition?

Opinions are divided on Wall Street, with at least one analyst wondering if a deal could be in the works and others casting doubt on the speculation.

Get the complete picture with a MassDevice Plus membership. Registered users can login here.